Explore 3 Stock Ideas & Industry Insights Download Free Report

Abattis Bioceuticals Corp

Healthcare US ATTBF

0.0USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

52 Week Range

-0.0001
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap0.01M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.83772M
  • Revenue TTM0.36M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.24M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2019-09-30 2018-09-30 2017-09-30 2016-09-30 2015-09-30
Type yearly yearly yearly yearly yearly
Date 2019-09-30 2018-09-30 2017-09-30 2016-09-30 2015-09-30
Income before tax -3.06100M -77.65057M -7.92612M -2.41218M -5.99295M
Minority interest -0.41009M -0.39109M -0.75323M -0.46118M -0.38391M
Net income -3.04201M -78.01271M -7.63406M -2.33942M -4.47255M
Selling general administrative 2.98M 12.63M 6.07M 2.05M 2.74M
Selling and marketing expenses 1.17M 3.14M 0.15M 0.08M 0.13M
Gross profit 0.24M 0.00648M 0.00000M 0.00000M 0.06M
Reconciled depreciation 0.11M 0.04M 0.12M - -
Ebit -3.95680M -17.37336M -6.36204M -2.30948M -3.35405M
Ebitda -3.84779M -17.33600M -6.24114M -2.17945M -3.17096M
Depreciation and amortization 0.11M 0.04M 0.12M 0.13M 0.18M
Non operating income net other - 0.00000M 0.00000M 0.00000M 0.00000M
Operating income -3.95680M -17.37336M -6.36150M -2.30505M -3.07776M
Other operating expenses 4.37M 15.84M 6.36M 2.31M 3.17M
Interest expense 0.05M 4.34M 0.00304M 0.03M 0.04M
Tax provision - - - 0.00000M -
Interest income - - - - -
Net interest income -0.04936M -4.33689M -0.00648M -0.03428M -
Extraordinary items - 0.00000M 0.00000M 0.00000M 0.00000M
Non recurring - 0.00000M 0.00000M 0.00000M 0.00000M
Other items - 0.00000M 0.00000M 0.00000M 0.00000M
Income tax expense 0.09M 3.16M -0.28611M -0.04292M -0.41929M
Total revenue 0.36M 0.00837M 0.00000M 0.00000M 0.09M
Total operating expenses 4.26M 15.84M 6.36M 2.31M 3.14M
Cost of revenue 0.12M 0.00189M 0.00000M 0.00000M 0.03M
Total other income expense net 1.00M -57.48293M -1.55814M -0.07285M -2.87366M
Discontinued operations - 0.00000M -0.87616M -0.87616M -0.87616M
Net income from continuing ops -3.06100M -77.65057M -7.92612M -2.41218M -5.57365M
Net income applicable to common shares -3.04201M -78.01271M -7.63406M -2.33942M -4.47255M
Preferred stock and other adjustments - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2019-09-30 2018-09-30 2017-09-30 2016-09-30 2015-09-30
Type yearly yearly yearly yearly yearly
Date 2019-09-30 2018-09-30 2017-09-30 2016-09-30 2015-09-30
Total assets 19.26M 11.40M 1.21M 1.27M 1.61M
Intangible assets 11.69M 0.00000M 0.00000M 1.03M 1.10M
Earning assets - - - - -
Other current assets 0.02M 0.77M 0.00000M 0.00000M 0.00684M
Total liab 8.59M 0.30M 0.44M 1.06M 1.14M
Total stockholder equity 11.08M 11.49M 1.52M 0.67M 0.86M
Deferred long term liab - 0.00000M 0.00000M 0.00000M 0.00000M
Other current liab 3.25M 0.08M 0.23M 0.42M 0.02M
Common stock 114.45M 108.84M 22.10M 14.71M 12.44M
Capital stock 114.45M 108.84M - - -
Retained earnings -101.70682M -99.79797M -22.74370M -15.15429M -13.58151M
Other liab 3.56M 0.00000M 0.00000M 0.00000M 0.00000M
Good will 3.16M 0.00000M 0.00000M 0.00000M 0.00000M
Other assets - 0.00000M 0.00200M 0.00200M 0.00200M
Cash 2.02M 4.06M 0.53M 0.04M 0.16M
Cash and equivalents - - - - -
Total current liabilities 4.91M 0.30M 0.44M 1.03M 1.14M
Current deferred revenue - - - - -
Net debt -0.44984M -4.06401M -0.52557M -0.00756M -0.16459M
Short term debt 1.45M 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt 1.42M 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt total 1.57M - - 0.03M -
Other stockholder equity -1.48078M 0.44M 2.34M 14.83M 14.32M
Property plant equipment 0.76M 0.73M 0.53M 0.15M 0.17M
Total current assets 3.60M 10.46M 0.68M 0.09M 0.35M
Long term investments 0.05M 0.21M 0.00000M 0.00000M 0.00000M
Net tangible assets -3.77407M 11.49M 1.52M -0.35510M -0.23584M
Short term investments 0.38M 5.03M 0.00000M 0.00000M 0.09M
Net receivables 0.16M 0.57M 0.13M 0.04M 0.04M
Long term debt - 0.00000M 0.00000M 0.03M 0.00000M
Inventory 0.27M 0.03M 0.00000M 0.00000M 0.00000M
Accounts payable 0.22M 0.22M 0.21M 0.61M 1.14M
Total permanent equity - 0.00000M 0.00000M 0.00000M 0.00000M
Noncontrolling interest in consolidated entity - 0.00000M 0.00000M 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests - 0.00000M 0.00000M 0.00000M 0.00000M
Accumulated other comprehensive income -0.18566M 2.00M -0.17797M 1.00M 0.12M
Additional paid in capital - 0.00000M 0.00000M 0.00000M 0.00000M
Common stock total equity - 0.00000M 0.00000M 0.00000M 0.00000M
Preferred stock total equity - 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings total equity - 0.00000M 0.00000M 0.00000M 0.00000M
Treasury stock - 0.00000M 0.00000M 0.00000M 0.00000M
Accumulated amortization - 0.00000M 0.00000M 0.00000M 0.00000M
Non currrent assets other -0.00000M 0.94M 0.00200M 0.00200M 0.00200M
Deferred long term asset charges - 0.00000M 0.00000M 0.00000M 0.00000M
Non current assets total 15.66M 0.94M 0.53M 1.18M 1.26M
Capital lease obligations 0.15M 0.00000M 0.00000M 0.00000M 0.00000M
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2019-09-30 2018-09-30 2017-09-30 2016-09-30 2015-09-30
Type yearly yearly yearly yearly yearly
Date 2019-09-30 2018-09-30 2017-09-30 2016-09-30 2015-09-30
Investments -6.45614M -12.00000M -12.00000M 0.08M 1.05M
Change to liabilities 1.37M -0.13621M 0.00000M 0.00000M 0.45M
Total cashflows from investing activities -11.51694M -16.23376M -0.43093M 0.04M 1.12M
Net borrowings - 0.00000M 0.00000M 0.03M 0.03M
Total cash from financing activities 0.06M 28.05M 2.14M 0.57M 0.72M
Change to operating activities 6.92M -0.08636M -0.01201M 0.31M 0.00723M
Net income -3.06100M -77.65057M -7.92612M -2.41218M -5.57365M
Change in cash -2.04486M 3.54M 0.49M -0.11927M 0.02M
Begin period cash flow 4.06M 0.53M 0.04M 0.16M 0.14M
End period cash flow 2.02M 4.06M 0.53M 0.04M 0.16M
Total cash from operating activities 9.41M -8.27946M -1.22240M -0.73321M -1.82353M
Issuance of capital stock 0.00000M 27.58M - - -
Depreciation 0.11M 0.04M 0.12M 0.13M 0.18M
Other cashflows from investing activities - -0.00000M -0.00000M 0.00684M 0.24M
Dividends paid - 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory -0.23737M -0.03045M 0.29M 0.29M 0.29M
Change to account receivables 0.39M -0.45911M -0.08953M 0.00063M 0.07M
Sale purchase of stock - 0.00000M 0.00000M 0.00000M 0.00000M
Other cashflows from financing activities -11.51694M 0.48M -0.43093M 0.03M 0.12M
Change to netincome 3.90M 70.41M 6.13M 1.17M 1.93M
Capital expenditures 5.06M 0.23M 0.43M 0.05M 0.15M
Change receivables - 0.00000M 0.00000M 0.00000M 0.00000M
Cash flows other operating - 0.00000M 0.00000M 0.00000M 0.00000M
Exchange rate changes - 0.00000M 0.00000M 0.00000M 0.00000M
Cash and cash equivalents changes - 0.00000M 0.00000M 0.00000M 0.00000M
Change in working capital 8.45M -0.71213M 0.19M 0.31M 0.54M
Stock based compensation 0.00162M 0.49M 0.72M 0.07M 0.24M
Other non cash items 3.91M 69.55M 5.68M 1.17M 3.21M
Free cash flow 4.35M -8.51320M -1.65333M -0.77891M -1.96948M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATTBF
Abattis Bioceuticals Corp
- -% - - - 0.04 0.38 11.43 -1.4047
ZTS
Zoetis Inc
-2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
-0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
- -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG
- -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

Profile

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Abattis Bioceuticals Corp

625 Howe Street, Vancouver, BC, Canada, V6C 2M6

Key Executives

Name Title Year Born
Mr. Robert J. Abenante BBA, CA, MPAcc Pres, CEO & Director 1983
Mr. Douglas J. Sorocco LLB Advisor 1971
Mr. Guy P. Dancosse CIRC, CRIA, ICD.D, Q.C. Advisor 1944
Mr. Francesco Paolini CFO & Director NA
Mr. Patrick Mitchell COO & Director NA
Mr. Shawn Balaghi Head of Corp. Devel. NA
Mr. Clayton Chessa Head of Operations NA
Mr. Jim Carter Head of Mergers and Acquisitions Advisory NA
Mr. Christopher P. Cherry C.A., C.P.A., CA, CGA, CPA Corp. Comptroller 1979
Ms. Nicole Breitinger Corp. Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.